We [24] and others [23] have previously shown that combining EGFR and MEK inhibitors can significantly impair resistance to EGFR inhibition in EGFRm positive NSCLC cell lines Moreover, we have shown that a subset of cell lines with acquired osimertinib display enhanced sensitivity to the MEK inhibitor selumetinib [24]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.